Core Insights - Spyre Therapeutics, Inc. presented preclinical findings at the 20th Congress of the European Crohn's and Colitis Organisation (ECCO) indicating that the combined inhibition of α4β7 integrin and TL1A cytokine is more effective than either treatment alone in mouse models of colitis [1][2] - The pharmacokinetic profiles of the antibodies SPY001 and SPY002 showed no drug-drug effects when administered together in non-human primates, suggesting potential for less frequent dosing in humans [2] Company Overview - Spyre Therapeutics is focused on developing next-generation therapies for inflammatory bowel disease (IBD) and other immune-mediated diseases through advanced antibody engineering and rational therapeutic combinations [3] - The company's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23, with ongoing research into their efficacy and dosing regimens [3]
Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation